Skip to main content Accessibility help

Disopyramide use in infants and children with hypertrophic cardiomyopathy

  • Matthew J. O’Connor (a1), Kelley Miller (a1), Robert E. Shaddy (a1), Kimberly Y. Lin (a1), Brian D. Hanna (a1), Chitra Ravishankar (a1) and Joseph W. Rossano (a1)...


Hypertrophic cardiomyopathy has a range of clinical severity in children. Treatment options are limited, mainly on account of small patient size. Disopyramide is a sodium channel blocker with negative inotropic properties that effectively reduces left ventricular outflow tract gradients in adults with hypertrophic cardiomyopathy, but its efficacy in children is uncertain. A retrospective chart review of patients ⩽21 years of age with hypertrophic cardiomyopathy at our institution and treated with disopyramide was performed. Left ventricular outflow tract Doppler gradients before and after disopyramide initiation were compared as the primary outcome measure. Nine patients received disopyramide, with a median age of 5.6 years (range 6 days–12.9 years). The median left ventricular outflow tract Doppler gradient before initiation of disopyramide was 81 mmHg (range 30–132 mmHg); eight patients had post-initiation echocardiograms, in which the median lowest recorded Doppler gradient was 43 mmHg (range 15–100 mmHg), for a median % reduction of 58.2% (p=0.002). With median follow-up of 2.5 years, eight of nine patients were still alive, although disopyramide had been discontinued in six of the nine patients. Reasons for discontinuation included septal myomectomy (four patients), heart transplantation (one patient), and side effects (one patient). Disopyramide was effective for the relief of left ventricular outflow tract obstruction in children with hypertrophic cardiomyopathy, although longer-term data suggest that its efficacy is not sustained. In general, it was well tolerated. Further study in larger patient populations is warranted.


Corresponding author

Corresponding to: M. J. O’Connor, Division of Cardiology, The Children’s Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, United States of America. Tel: +267 426 5700; Fax: +267 426 9800; E-mail:


Hide All
1. Maron, BJ, Rowin, EJ, Casey, SA, et al. Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation 2016; 133: 6273.
2. Bharucha, T, Lee, KJ, Daubeney, PEF, et al. Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. J Am Coll Cardiol 2015; 65: 23022310.
3. LaPage, MJ, Bradley, DJ, Dick, M. Verapamil in infants: an exaggerated fear? Pediatr Cardiol 2013; 34: 15321534.
4. Sherrid, MV, Pearle, G, Gunsburg, DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998; 97: 4147.
5. Sherrid, MV, Arabadjian, M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis 2012; 54: 483492.
6. Sherrid, MV, Barac, I, McKenna, WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45: 12511258.
7. Sherrid, MV, Shetty, A, Winson, G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. Circ Heart Fail 2013; 6: 694702.
8. Teraguchi, M, Ikemoto, Y, Kobayashi, Y. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy. Circ J 2002; 66: 709711.
9. Duncan, WJ, Tyrrell, MJ, Bharadwaj, BB. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can J Cardiol 1991; 7: 8186.
10. Baker, EJ, Hayler, AM, Curry, PVL, et al. Measurement of plasma disopyramide as a guide to paediatric use. Int J Cardiol 1986; 10: 6569.
11. Gersh, BJ, Maron, BJ, Bonow, RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e783e831.
12. Altarabsheh, SE, Dearani, JA, Burkhart, HM, et al. Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. Ann Thorac Surg 2013; 95: 663669.
13. Hickey, EJ, McCrindle, BW, Larsen, SH, et al. Hypertrophic cardiomyopathy in childhood: disease natural history, impact of obstruction, and its influence on survival. Ann Thorac Surg 2012; 93: 840848.
14. Poterucha, JT, Johnson, JN, O’Leary, PW, et al. Surgical ventricular septal myectomy for patients with Noonan syndrome and symptomatic left ventricular outflow tract obstruction. Am J Cardiol 2015; 116: 11161121.


Disopyramide use in infants and children with hypertrophic cardiomyopathy

  • Matthew J. O’Connor (a1), Kelley Miller (a1), Robert E. Shaddy (a1), Kimberly Y. Lin (a1), Brian D. Hanna (a1), Chitra Ravishankar (a1) and Joseph W. Rossano (a1)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed